In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fruit for the 130 year-old family-owned drugmaker.
As chief information officer, a role he left in March 2018, he led the establishment of the firm’s innovation hub, BI X, based in a refurbished cluster of low-lying buildings that formerly housed a casino for guests at the firm’s sprawling campus in Ingelheim.
Tasked with bringing forward new and potentially disruptive platforms, engineers at BI X must pass a simple test to proceed: convince the “digital board” with a simple five-minute presentation, followed by five minutes for follow up questions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze